Bevor Sie zu YouTube weitergehen

Ascent Industries (NASDAQ:ACNT) said it is intentionally shifting revenue from custom manufacturing toward product sales, which it expects to be more predictable and margin accretive. Product sales rose from ~10% of sales in 2023 to ~27% in 2024 and ~30% last year. Management cited $7M and $10M net-new business from recent customer wins, underutilized assets (~45% utilization), and a $14M Midwest Graphic Sales acquisition (closed early May) with $10.8M revenue and ~$2M adjusted EBITDA.

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

Whirlpool (NYSE: WHR) reported early results for its cash tender offer to purchase its 1.250% notes due 2026 and 1.100% notes due 2027, plus a consent solicitation to amend the 2027 notes indenture, as of June 12, 2026. The company plans early settlement around June 18, 2026 and expects $2.0 billion of new senior secured notes financing.

Baffinland Iron Mines said Ontario Superior Court granted it immediate access to US$110M (C$154M) funding and extended creditor protection, keeping a stay of proceedings until Aug. 28. A June 30 hearing will decide whether it can keep its $400M debtor-in-possession financing from Export Development Canada or replace it. The company forecast cash burn of about $217M through Aug. 28.

Lotus Technology Inc. (Nasdaq: LOT) said it is advancing its planned acquisition of Lotus UK, expected to close in 2026, to support a “One Lotus” strategy and integration synergies. The company temporarily suspended earnings releases for Q1 and Q3 2026 to prioritize acquisition-related compliance, while continuing to report the first half and full fiscal year 2026.

XORTX Therapeutics Inc. (NASDAQ: XRTX; TSXV: XRTX) said it has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company cited costs and administrative burden from maintaining a dual listing and differences in regulatory environments. It expects no shareholder action; Canadian shareholders will still trade on Nasdaq.